Probatebeta
Target

EPOR

Erythropoietin receptor

As of the edition of 20 October 2026, EPOR (erythropoietin receptor, UniProt P19235) has 11 drugs tested at it and 12 companies on the list, 2 on route A and 3 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P19235
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
21
Disease areas
Blood and lymph; Urinary and reproductive; Pregnancy and women's health; Cancer; Immune system; Heart and blood vessels; Nervous system; Infections
Registered trials of its drugs
529

Drugs at this target

StatusCount
Marketed6
Active1
Went quiet1
Stopped1
Withdrawn from market2
Total11
DrugStatusFurthest phaseUS protection
Epoetin alfaMarketedPhase 4Ended 2001
Darbepoetin alfaMarketedPhase 4Ended 2013
Methoxy polyethylene glycol-epoetin betaMarketedPhase 4Ended 2019
Epoetin betaMarketedPhase 4none listed
PeginesatideWithdrawn from marketPhase 4none listed
CibinetideStoppedPhase 2none listed
Efepoetin alfaActivePhase 3none listed
Epoetin deltaWithdrawn from marketPhase 4none listed
Epoetin zetaMarketedPhase 4none listed
HX575Went quietPhase 3none listed
Epoetin thetaMarketedNo phase statednone listed

11 of 11 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A2
Route B3
Engaged2
Undetermined5
Total on the list12
Three companies on route A or B, with the route only
CompanyRoute
TakedaRoute A
Johnson & JohnsonRoute B
JCR PharmaceuticalsRoute B

The other 9 companies at EPOR

In the product

12 companies in all; 9 are not named here, and no score is.

See the 12 companies at EPOR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

Other targets in blood and lymph

Companies holding approvals at EPOR